Karyopharm Therapeut KPTI

$0.83 +0.35 (73.35%)

Valuation

Market cap
10,935,000
Revenue TTM
$146,070,000
Net income TTM
$-196,040,000
PE ratio
0.00
Forward PE
—
Profit margin
-134.21%
Debt to equity
-0.38

Trading

Volume
55,142,199
Avg volume
1,505,872
Day's range
$0.46 – $0.91
Shares out
22,681,000
Stochastic %K
69%
Beta
1.04
Analysts
Strong Sell
Price target
$8.80

Price

Company profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead...

Show more

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 658 0600
Website
https://www.karyopharm.com
Address
85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States

Latest news

Stocktwits

pblegend66 Oct 29, 12:00 AM
$KPTI so ”Hope” isn't a trading strategy. got it, and I agree. So what is? Is it lying? because thats what you did twice already today. You told people that there was already a filed offering on the SEC website. Shocker: there wasn’t. but you lied about it twice. also, thank you for your public service announcement. It definitely sounds like you‘re doing it out of good for the public. it’s definitely not because you are short and lost your shirt today. bless your heart.
1 replies
ScrotieMcBoogerballs666 Oct 29, 12:00 AM
$KPTI
1 replies
JAMESAMEXBLACK Oct 28, 11:57 PM
$KPTI 🔻🔻🔻🔻🔻🔻🔻🔻🔻🔻🔻🚮🗑️
0 replies
JAMESAMEXBLACK Oct 28, 11:55 PM
$KPTI 🔻🔻🔻🔻🔻🔻🔻🔻🔻🔻🔻🔻🔻🔻
0 replies
Tygalastkings187 Oct 28, 11:51 PM
$KPTI 🤡
0 replies
JAMESAMEXBLACK Oct 28, 11:46 PM
$KPTI Serious financial concerns here. When a company faces significant financial pressure, shareholders need to consider the risks of additional financing, potential dilution, and continued downward pressure on the stock. Don’t confuse a beaten-down stock with a bargain. Without meaningful improvement in the company’s financial position, further downside remains a real risk. Protect your capital. Hope isn’t a trading strategy. 🚮🔻🔻🔻 Bearish opinion, not financial advice.
0 replies
Slick1194 Oct 28, 11:26 PM
$KPTI 4 days left till November 1st...that's when news will hit
1 replies
TeamBullish Oct 28, 11:25 PM
Biggest takeaway from today is managing expectations. Not every entry or momentum trigger is going to produce an immediate parabolic move. Conviction comes from understanding supply and demand, recognizing healthy retracements, and knowing exactly where a setup invalidates. Too many traders enter positions without understanding the underlying price structure or downside risk. A retracement doesn’t necessarily mean a breakdown in trend. Understanding that distinction is critical to managing positions objectively. Overall, a trickier session, but we’re seeing some constructive consolidation developing after-hours amongst $AIOK, $KPTI, $FTFT, $BRAI, and $NCPL. Should have some decent data to work with for tonight’s watchlist.
1 replies